Kinaset Advances Inhaled Pan-JAK Inhibitor For Broad Use In Severe Asthma

 
• By Ayisha Sharma

Emerging Company Profile: The US biotech acquired its sole asset from CDMO Vectura in 2020 and is now gearing up for a Phase II proof-of-concept trial in severe asthma to help address the unmet need in non-eosinophilic patients.  

Emerging Company Profile: Kinaset Therapeutics
Severe Asthma Patients Can Experience Exacerbations • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs